Only about 3% of children follow the 'atopic march' from eczema to asthma to hay fever
Two birth cohorts totalling 9,801 children were sorted into eight developmental patterns. The classic progression was one of them, and one of the smallest.
Peanut immunotherapy raises the dose children tolerate — and their anaphylaxis risk
Both things are true, and both rest on high-certainty evidence. The phase 3 trial and the meta-analysis that followed it measured different outcomes and reached opposite-sounding conclusions.
Feeding infants peanut early prevents allergy. The old advice to avoid it backfired.
The LEAP trial cut peanut allergy in high-risk infants from 13.7% to 1.9%. A second trial found the benefit real but harder to achieve — and only in children who actually ate the food.
Feeding peanut to high-risk infants cut peanut allergy from 13.7% to 1.9%
The LEAP trial reversed a generation of avoidance advice. A second trial run in the general population missed its primary endpoint, and the distance between those two results is the part usually left out.